Is N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) a marker for Kawasaki disease myocarditis?

NT-proBNP as a Marker for Kawasaki Disease Myocarditis

NT-proBNP is elevated in Kawasaki disease and likely reflects myocardial involvement, but it lacks sufficient discriminative ability to serve as a standalone diagnostic marker for KD myocarditis, and standardized cut-point values have not been established. 1

Clinical Context and Mechanism

The American Heart Association's 2017 scientific statement explicitly addresses this question: NT-proBNP may be elevated in some KD patients, "likely indicative of myocardial involvement," but emphasizes that this biomarker does not have adequate discriminative ability to differentiate KD from other conditions, and no clear cut-point values exist for clinical use 1. This is the authoritative guideline position that should frame clinical decision-making.

Evidence Supporting NT-proBNP Elevation in KD Myocarditis

The mechanism behind NT-proBNP elevation relates directly to myocardial inflammation:

• Myocarditis is nearly universal in acute KD, affecting the pericardium, myocardium, endocardium, and coronary arteries 1
• NT-proBNP is released by cardiomyocytes in response to mechanical factors (cardiac chamber dilation) and pro-inflammatory cytokines 2
• Elevated NT-proBNP correlates with subclinical myocardial dysfunction, including decreased left ventricular shortening fraction, increased LV mass, and elevated E/e' ratio (diastolic dysfunction marker) 3
• NT-proBNP levels correlate positively with cardiac troponin I, a sensitive marker of cardiac injury 4

Diagnostic Performance

Research demonstrates that NT-proBNP has moderate diagnostic utility:

• Pooled sensitivity of 89% (95% CI: 78-95) and specificity of 72% (95% CI: 58-82) for KD diagnosis 2
• Positive likelihood ratio of 3.2:1 2
• KD patients have significantly higher NT-proBNP than febrile controls (mean 923.6 vs 186.2 ng/L, p<0.001) 5
• Recent 2026 data shows good diagnostic accuracy with AUC of 0.85 for detecting coronary artery lesions 6

Critical Limitations

The non-specificity of NT-proBNP severely limits its clinical utility:

• Cannot be used as a stand-alone diagnostic test 2
• No validated cut-point values exist for clinical practice 1
• Elevated in multiple other conditions causing myocardial stress or inflammation
• The AHA guideline states it is "not superior to elevated CRP or ESR" for KD diagnosis 1

Practical Clinical Application

Use NT-proBNP as an adjunctive marker in specific scenarios:

1. Incomplete KD cases where clinical criteria are insufficient—elevated NT-proBNP (>2-3 times normal) supports the diagnosis when combined with other findings 5, 7

2. Risk stratification—higher NT-proBNP levels associate with:

   • IVIG resistance 2
   • Coronary artery lesions 6
   • Need for escalated therapy (e.g., infliximab) 8

3. Monitoring myocardial recovery—NT-proBNP decreases significantly during convalescence (from ~636 to ~164 ng/L), reflecting resolution of myocardial inflammation 4

Common Pitfalls to Avoid

• Do not rely on NT-proBNP alone to diagnose or exclude KD myocarditis
• Do not use it to replace echocardiography for assessing cardiac involvement
• Remember that normal NT-proBNP does not exclude KD—approximately 36% of KD patients have normal levels 3
• NT-proBNP elevation reflects myocardial involvement but does not predict long-term cardiac outcomes independently

Bottom Line for Clinical Practice

NT-proBNP is a supportive biomarker that reflects the myocardial inflammatory component of KD. Use it to strengthen diagnostic confidence in incomplete cases and for risk stratification, but always interpret it within the full clinical context alongside standard inflammatory markers (ESR, CRP), echocardiography, and clinical criteria. The 2017 AHA guidelines remain clear that no biomarker, including NT-proBNP, has proven superior to traditional inflammatory markers for KD diagnosis 1.